1) Antoniou A, et al : Average risks of breast and ovarian cancer associated with BRCA1 or BRCA2 mutations detected in case Series unselected for family history : a combined analysis of 22 studies. Am J Hum Genet 72 : 1117─1130, 2003(Erratum : 73 : 709, 2003)
2) Ford D, et al : Risks of cancer in BRCA1-mutationcarriers. Breast Cancer Linkage Consortium. Lancet 19 : 343 : 692─695, 1994
3) King MC, et al : Breast and ovarian cancer risks due to inherited mutations in BRCA1 and BRCA2. Science 302 : 643─646, 2003
4) Rebbeck TR, et al : Meta-analysis of risk reduction estimates associated with risk-reducing salpingo−oophorectomy in BRCA1 or BRCA2 mutation carriers. J Natl Cancer Inst 101 : 80─87, 2009
5) Domchek SM, et al : Association of risk-reducing surgery in BRCA1 or BRCA2 mutation carriers with cancer risk and mortality. JAMA 304 : 967─975, 2010
6) Rebbeck TR, et al : Effect of short-term hormone replacement therapy on breast cancer risk reduction after bilateral prophylactic oophorectomy in BRCA1 and BRCA2 mutation carriers : the PROSE Study Group. J Clin Oncol 23 : 7804─7810, 2005
7) Kathryn A, et al : BRCA Mutation Frequency and Patterns of TreatmentResponse in BRCA Mutation-Positive Women WithOvarian Cancer : A Report From the Australian Ovarian Cancer Study Group. J Clin Oncol 30 : 2654─2663, 2012
8) Eisen A, et al : Breast cancer risk following bilateral oophorectomy in BRCA1 and BRCA2 mutation carrieers : an international case-control study. J Clin Oncal 23 : 7491─7496, 2005
9) Domchek SM, et al : Occult ovarian cancers identified at risk-reducing salpingooophorectomy in a prospective cohort of BRCA1/2 mutation carriers. Breast Cancer Res Treat 124 : 195─203, 2010
10) Leeper K, et al : Pathologic findings in prophylactic oophorectomy specimens in high-risk women. Gynecol Oncol 87 : 52─56, 2002